Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Study sponsor: Alaunos Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-08-05Actual
Enrollment · participants40Actual
Source updated2025-04-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.